JP2017529322A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529322A5
JP2017529322A5 JP2017505548A JP2017505548A JP2017529322A5 JP 2017529322 A5 JP2017529322 A5 JP 2017529322A5 JP 2017505548 A JP2017505548 A JP 2017505548A JP 2017505548 A JP2017505548 A JP 2017505548A JP 2017529322 A5 JP2017529322 A5 JP 2017529322A5
Authority
JP
Japan
Prior art keywords
moiety
polymer
integer
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505548A
Other languages
English (en)
Japanese (ja)
Other versions
JP6704900B2 (ja
JP2017529322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043297 external-priority patent/WO2016019340A1/en
Publication of JP2017529322A publication Critical patent/JP2017529322A/ja
Publication of JP2017529322A5 publication Critical patent/JP2017529322A5/ja
Application granted granted Critical
Publication of JP6704900B2 publication Critical patent/JP6704900B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505548A 2014-07-31 2015-07-31 ポリオキサゾリン抗体薬物複合体 Active JP6704900B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031382P 2014-07-31 2014-07-31
US62/031,382 2014-07-31
PCT/US2015/043297 WO2016019340A1 (en) 2014-07-31 2015-07-31 Polyoxazoline antibody drug conjugates

Publications (3)

Publication Number Publication Date
JP2017529322A JP2017529322A (ja) 2017-10-05
JP2017529322A5 true JP2017529322A5 (enExample) 2018-08-30
JP6704900B2 JP6704900B2 (ja) 2020-06-03

Family

ID=55178936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505548A Active JP6704900B2 (ja) 2014-07-31 2015-07-31 ポリオキサゾリン抗体薬物複合体

Country Status (7)

Country Link
US (2) US10071168B2 (enExample)
EP (1) EP3180388A4 (enExample)
JP (1) JP6704900B2 (enExample)
KR (1) KR20170046141A (enExample)
CN (1) CN106715533B (enExample)
CA (1) CA2956709A1 (enExample)
WO (1) WO2016019340A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502226A (ja) * 2016-12-23 2020-01-23 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 薬物の標的送達のための生体適合性の親水性ポリマーコンジュゲート
WO2020188323A1 (en) * 2019-03-18 2020-09-24 Khashayar Karimian Mate and separate: a convenient and general method for the separation and purification of target molecules from biological media by phase transition of pegylated recognition agents.
US12527871B2 (en) 2019-06-05 2026-01-20 Boston Scientific Scimed, Inc. Click chemistry capturable platinum-based antineoplastic agents
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
EP4430076A2 (en) * 2021-11-08 2024-09-18 Life Technologies AS Polymer-interaction molecule conjugates and methods of use
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20250288682A1 (en) * 2022-04-26 2025-09-18 University Of Virginia Patent Foundation Development of nano-encapsulated fatty-acyl conjugated colchicine
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP2134181A4 (en) * 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5514736B2 (ja) * 2008-01-11 2014-06-04 セリナ・セラピユーテイツクス・インコーポレーテツド ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
SI2528625T1 (sl) * 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20160024252A1 (en) * 2011-08-03 2016-01-28 Anp Technologies, Inc. Oxazoline Polymer Compositions and Use Thereof
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates

Similar Documents

Publication Publication Date Title
JP2017529322A5 (enExample)
JP2016153410A5 (enExample)
JP2006502741A5 (enExample)
JP2023098946A5 (enExample)
JP2012512898A5 (enExample)
JP2010521485A5 (enExample)
RU2020123953A (ru) Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
JP2014231516A5 (enExample)
RU2008110495A (ru) Конъюгаты лиганда с несколькими лекарственными средствами
RU2011129764A (ru) Лекарственные средства, связанные с дипептидами
JP2020519643A5 (enExample)
JP2008528658A5 (enExample)
JP2009504784A5 (enExample)
JP2013531659A5 (enExample)
JP2007502293A5 (enExample)
RU2006105101A (ru) Арилокси и арилалкиленокси замещенные имидазохинолины
RU2013142179A (ru) Способы получения конъюгатов
JP2022527449A5 (enExample)
RU2009105670A (ru) Высокомолекулярный конъюгат комбретастатинов
JP2007511527A5 (enExample)
JP2006523437A5 (enExample)
JP2014520120A5 (enExample)
JP2008504237A5 (enExample)
JP2023504445A5 (enExample)
NZ762865A (en) Psma-targeting amanitin conjugates